Intravitreal ranibizumab (Lucentis, Genentech) appears to be effective for treatment of severe retinopathy of prematurity (ROP) and associated with less persistent suppression of systemic VEGF compared with bevacizumab (Avastin, Genentech), according to research reported by Shunji Kusaka, MD.
“Some previous studies also showed very transient systemic suppression in infants treated with intravitreal ranibizumab for ROP, but our study provides the largest dataset,” said Dr. Kusaka, professor of ophthalmology, Kindai University Sakai Hospital, Osaka, Japan.
He acknowledged that the study he presented still has a small sample size along with several other limitations—it was not a randomized controlled trial, it had short-term follow-up, and safety profiles were not investigated.
“At least in the short-term, however, we did not see any efficacy difference between bevacizumab and ranibizumab,” Dr. Kusaka said. “If we are thinking about systemic safety, maybe in the future we should use ranibizumab instead of bevacizumab.”